about dan watson

image55
image56
image57

about dan watson

image58

Since 2010 I have been focused on researching and investing in Pharmaceutical, Biotech, and Medical Technology companies. I focus on companies that are developing medicines or have developed medicines for diabetes, Alzheimer’s, cancer, hepatitis, Crohn’s disease, and others. I have been very successful with this investment strategy since 2009. My first successful healthcare/biotech investment was on March 12th, 2009 when Roche® purchased a biotechnology company that I held stock in - Genentech®. Roche’s purchase of Genentech for $46.8 Billion was the motivation to review the entire healthcare sector.  Highlighted below are companies that I have or have had long positions in since 2010 and I will occasionally trade in and out these companies.  From my perspective the biotech sector has been on a bull run since 2009. On February 7th, 2018, 2 days after the ^VIX inspired high volatility crash/correction on February 5th and 6th of 2018, I again went “all in” on the Healthcare sector. More importantly the cancer death rate in the U.S. fell 13% from 2004 to 2013 according to those who track such information.

Please be advised that I am not a financial adviser/investment adviser, and I have no business relationship with any of the company’s who are mentioned below. I have worked for Unilever®, Grey Advertising®, Hasbro®, Toys R Us® and other companies prior to 2010.   I consider myself, insightful regarding trends and products, market timing, identifying long-term value situations, long-term brand development, and identifying technologies and products that will be highly profitable.  I do not “blog” often, as I spend more time processing information then communicating data.  I have been following many Seeking Alpha writers as a member since 2012.  I also gain information/data/charts from many other sources. And have many business and company alerts directly sent to me on their products, and product tests involving new medicines.  These are extraordinary times for investing and processing new products and ventures and is not limited to the healthcare sector.  However, the amounts of money being devoted to new medical technologies and new medicines is remarkable. 

  

As of 6/19/2019 I remain 100% invested in biotech/medtech companies, (except for a few shares Lowe's stock) My reasons are as follows:

1. Healthcare is the right category for growth over next 10+ years, as I agree with comments from Russ Koesterich of BlackRock® on September 19, 2018  www.blackrock.com/... 

"At $3.5 trillion per year, total healthcare spending (public and private) makes up roughly 20% of the U.S. economy. The nation's 80 million baby boomers provide a stable source of ongoing revenue growth for healthcare companies throughout the value chain. Demographic tailwinds are widely expected to continue to propel this secular story in the United States."

2. Healthcare is the right category for mergers; e.g. ($BMY) recent acquisition of ($CELG) and ($LLY) recent acquisition of (LOXO) and on 6/17/2019  Pfizer is buying Array (ARRY) 

3. Healthcare is also a defensive category if things turn south as many company pipelines and product development will continue to progress. 

4. The biotech sector is increasingly becoming an effort to seek stronger partnership (seeking biotech partnerships).  Many companies are developing new drugs that can in many instances work better in combination with other successful/newer drugs or help other drugs work better against specific medical issues when used in combination.  

5. Both biotech and medtech companies are also increasing their partnerships with biotechnology focused colleges and medical universities/hospitals towards successful co-product development partnerships. This is occurring on a global basis. 

 I also like following companies that have dividend growth and great new products and pipelines - ($LLY), ($MDT), ($PFE), ($MRK), ($AZN), ($A)
my top biotech picks are here =
seekingbiotechalpha.com/...
my top medtech picks are here =
seekingbiotechalpha.com/...
my top growth picks (no dividends) - ($
ISRG), ($ABMD), ($ILMN), ($BIIB), ($REGN), ($VRTX), ARRY,  (SRPT)
 

Before February 5th, 2018 I was a passive investor, no longer. I am now an active supporter of all the healthcare, medical, and biotech companies that I hold stock in.  Please be advised that this is not investment advise, these are my investments.  Thank you for visiting seeking biotech alpha and please feel free to send me comments/feedback/questions.  My best to all in 2019, as we may continue to see chaotic volatility again.  
(CELG), (ABBV), (AMGN), (BMY), (JNJ), (ABT), (LLY), (MRK), (PFE), (NVS), (NVO), (BIIB), (MDT), (ABMD), (ISRG), (AZN), (RHHBY), (GILD), (REGN), (GERN), (BGNE), (SGMO), (BMRN), (VRTX), (ILMN), (A), (PKI), (INCY), (TMO), (SRPT),(ARRY)

Thank you for visiting www.seekingbiotechalpha.com and 


Roche Agrees to Buy Genentech for $46.8 Billion - The New York Times

danwatson.com

image59

dan watson @ Linkedin

image60

about dan watson

image61

comments and blogs posted on seeking alpha  

dan watson @ Seeking Alpha
image62

  "The Little Toy Company That Could" 

LARAMI 

dan watson @ larami
image63

 dan watson's real time 24/7 portfolio - seeking biotech alpha  @ GuruFocus

seeking biotech alpha portfolio 24/7 @ GURUFOCUS

Help with Your Diabetes Prescription and Insulin Costs

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)

image67

 

  • The Patient Assistance Program

The Lilly Diabetes Solution Center

image68

 

  • Lilly Diabetes Solution Center Offers Insulin Affordability Assistance

The Novo Nordisk Patient Assistance Program (PAP)

image69

  •  Patient Assistance Program 

image70

Help with Your Diabetes Prescription and Insulin Costs

Sanofi Patient Connection™

image71

 For U.S. Residents Only 

 Patient Connection Application

 Help with Your Diabetes Prescription and Insulin Costs

image72

The 10 Hottest Bioincubators in Europe

"We are building the Next Generation of Digital Media for Biotech" Philip, Joachim and Labiotech.eu

 A Bioincubator is a launch-pad structure for entrepreneurs to make their project in the sciences real. In Europe, we have many incubators within each industry, responsible for strategic investment, development and providing a support network for start-ups. 


 Sectors: Pharmaceutical and Agricultural. 


 Sectors: Biotechnology 


 Sectors: Biotherapies, Genetics, Biotechnology 


 Sectors:  Immuno-Oncology 


 Sectors: Life Sciences 


 Sectors: Agrifood, Bioeconomy and Life Sciences 


 Sectors: Biotechnology and Health 


 Sectors:  Healthcare and Pharmaceuticals 

image73

From prison to park: Camden's Cooper's Poynt Phaedra Trethan

A Prison Falls, a Playground Rises in North Camden By Matt Skoufalos | June 5, 2017

 Overhauling the site was a project that took decades and millions of dollars. The Delaware River Port Authority allocated $8 million for demolition of the prison, and the New Jersey Economic Development Authority (EDA) supplemented that with $5 million in planning and infrastructure grants. 

 


The Wells Fargo Regional Foundation kicked in $750,000 for a neighborhood planning grant, and the William Penn Foundation added another quarter-million dollars for the bikeway improvements. 


 

There are plans to construct a mixed-use commercial-residential development on the surrounding property at Cooper’s Poynt, but the EDA still hasn’t found qualified developers to take on the project.

Maureen Hassett, EDA senior vice president of governance, communications, and strategic initiatives, said the agency is evaluating options for the land, which is still owned by the New Jersey Department of Corrections. 


 

Rodney Sadler, Executive Director of the Save Our Waterfront neighborhood coalition, recollected the years of work that went into salvaging the property, from opposing construction of the prison to the day it was leveled.

“It made a difference,” Sadler said. “It made it possible.” 


 A Prison Falls, a Playground Rises in North Camden 


Cooper’s Poynt Playground. Credit: Matt Skoufalos.

“There needs to be that other connection,” Sadler said. “It has to start somewhere.”

 

Cooper's Poynt Park, 801-811 Delaware Ave, Camden, NJ 08102

A Prison Falls, a Playground Rises in North Camden By Matt Skoufalos June 5, 2017 NJPEN.com